GLP-1 receptor agonists (like semaglutide) are medications that mimic the action of natural GLP-1 in your body
Since many patients with type 2 diabetes and CKD remain at high risk of kidney failure despite optimal guideline therapy, the development of new therapies has to continue
Always work with a qualified healthcare professional before starting, stopping, or changing any peptide, medication, or body-composition protocol.
"Many in our community, and especially those in the lower socioeconomic bracket, they find these treatments are financially out of reach," said Priti Chawla, executive director of Obesity Matters
The NHS does not recommend GLP-1 medications for thyroid conditions unless concurrent diabetes or obesity criteria are met